Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity
暂无分享,去创建一个
Luca Passamonti | James B. Rowe | Trevor W. Robbins | Alexander G. Murley | Maria Grazia Spillantini | Kieren S. J. Allinson | Sanne Simone Kaalund
[1] F. E. Bloom,et al. Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type , 1983, Neuroscience Letters.
[2] Yasuo Terayama,et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.
[3] A. Investigators. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. , 2016 .
[4] J. Rowe,et al. Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration , 2019, bioRxiv.
[5] J Bohl,et al. Spatial, Temporal and Numeric Analysis of Alzheimer Changes in the Nucleus Coeruleus , 1997, Neurobiology of Aging.
[6] H. Braak,et al. The pathological process underlying Alzheimer’s disease in individuals under thirty , 2011, Acta Neuropathologica.
[7] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[8] J. Rowe,et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.
[9] Richard E. Coggeshall,et al. A consideration of neural counting methods , 1992, Trends in Neurosciences.
[10] Luca Passamonti,et al. Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease , 2016, Neuropsychopharmacology.
[11] Christine M. Walsh,et al. Profound degeneration of wake-promoting neurons in Alzheimer's disease , 2019, Alzheimer's & Dementia.
[12] Richard J. Binney,et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year , 2016, Neurology.
[13] Luca Passamonti,et al. [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy , 2018, Neurology.
[14] Early neurone loss in Alzheimer’s disease: cortical or subcortical? , 2015, Acta neuropathologica communications.
[15] J. Bohl,et al. Unbiased Estimation of Neuronal Numbers in the Human Nucleus Coeruleus during Aging , 1997, Neurobiology of Aging.
[16] C. Jack,et al. MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy , 2018, Movement disorders : official journal of the Movement Disorder Society.
[17] Oliver Speck,et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases , 2019, Brain : a journal of neurology.
[18] T. Robbins,et al. Noradrenergic modulation of cognition: Therapeutic implications , 2013, Journal of psychopharmacology.
[19] Roger A. Barker,et al. Targeting impulsivity in Parkinson’s disease using atomoxetine , 2014, Brain : a journal of neurology.
[20] D. Weinshenker. Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease , 2018, Trends in Neurosciences.
[21] J. Neuhaus,et al. Locus coeruleus volume and cell population changes during Alzheimer's disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery , 2017, Alzheimer's & Dementia.
[22] John R Hodges,et al. The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening , 2006, International journal of geriatric psychiatry.
[23] Gary Aston-Jones,et al. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease , 2012, Front. Behav. Neurosci..
[24] L. Greene,et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Sulzer,et al. Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease , 2018, npj Parkinson's Disease.
[26] J. Rowe,et al. Neurotransmitter deficits from frontotemporal lobar degeneration , 2018, Brain : a journal of neurology.
[27] D. German,et al. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter‐2: Human midbrain dopamine neurons , 2004, The Journal of comparative neurology.
[28] C. Jack,et al. Modeling trajectories of regional volume loss in progressive supranuclear palsy , 2013, Movement disorders : official journal of the Movement Disorder Society.
[29] K. G. Baker,et al. The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study , 2004, Experimental Brain Research.
[30] L Passamonti,et al. The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration , 2018, Current Opinion in Behavioral Sciences.
[31] P. Yates,et al. The pathology of the human locus ceruleus. , 1983, Clinical neuropathology.
[32] L. Golbe,et al. A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.
[33] E. Mufson,et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease , 2017, Acta Neuropathologica Communications.
[34] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[35] Frank Jessen,et al. In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults , 2017, NeuroImage.
[36] Shosuke Ito,et al. Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus , 2015, Journal of neurochemistry.
[37] Eduardo E. Benarroch,et al. Locus coeruleus , 2020, Cell and Tissue Research.
[38] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[39] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[40] Christine M. Walsh,et al. Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study , 2018, Journal of neuropathology and experimental neurology.
[41] Clifford R Jack,et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial , 2014, The Lancet Neurology.
[42] Young T. Hong,et al. PET markers of tau and neuroinflammation are co-localized in progressive supranuclear palsy , 2019 .
[43] D. Dickson,et al. In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy , 2019, Movement disorders : official journal of the Movement Disorder Society.
[44] H. Braak,et al. Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff , 2017, Journal of Parkinson's disease.
[45] Hans Jørgen G. Gundersen,et al. Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals , 1994, Journal of Chemical Neuroanatomy.
[46] Roger A. Barker,et al. The Cambridge Behavioural Inventory revised , 2008, Dementia & neuropsychologia.
[47] O. Rascol,et al. Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy , 1998, Movement disorders : official journal of the Movement Disorder Society.
[48] J. Olszewski,et al. Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .
[49] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[50] B. Pakkenberg,et al. Increased volume of the pigmented neurons in the locus coeruleus of schizophrenic subjects: a stereological study. , 2005, Journal of psychiatric research.
[51] E. Düzel,et al. Commentary: Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice , 2018, Front. Neurosci..
[52] D. Sulzer,et al. Neuromelanin Activates Microglia and Induces Degeneration of Dopaminergic Neurons: Implications for Progression of Parkinson’s Disease , 2009, Neurotoxicity Research.
[53] J. Schneider,et al. Neural reserve, neuronal density in the locus ceruleus, and cognitive decline , 2013, Neurology.
[54] T. Robbins,et al. Apathy and impulsivity in frontotemporal lobar degeneration syndromes , 2016, Brain : a journal of neurology.
[55] Roger A. Barker,et al. Improving Response Inhibition in Parkinson’s Disease with Atomoxetine , 2015, Biological Psychiatry.
[56] D. C. Sterio. The unbiased estimation of number and sizes of arbitrary particles using the disector , 1984, Journal of microscopy.
[57] Alberto Gatti,et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[58] C. Jack,et al. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. , 2016, Parkinsonism & related disorders.
[59] V. Chan‐Palay,et al. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression , 1989, The Journal of comparative neurology.
[60] David R Williams,et al. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges , 2009, The Lancet Neurology.
[61] C. Berridge,et al. The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes , 2003, Brain Research Reviews.
[62] M. Mesulam,et al. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease , 2007, Neurobiology of Aging.